REG - Futura Medical PLC - Block Listing Six Monthly Return

Futura MedicalAnnouncement

Mon 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA5220Ga&default-theme=true

RNS Number : 5220G  Futura Medical PLC  01 June 2026

1 June 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Block Listing Six Monthly Return

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that
specialises in the development and global commercialisation of innovative and
clinically proven sexual health products, makes the following update on its
block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies. All figures relate to options over Ordinary Shares of 0.2 pence
each (Ordinary Shares).

 

 Name of applicant:                                                                  Futura Medical Plc
 Name of scheme(s):                                                                  Unapproved Share Option Scheme

                                                                                     Unapproved Share Incentive Scheme

                                                                                     EMI Share Option Scheme

                                                                                     LTIP Scheme
 Period of return:                         From:                                     9 December 2025     To:                 31 May 2026
 Balance of unallotted securities under scheme(s) from previous return:              16,237,570
 Plus:  The amount by which the block scheme(s) has been increased since the         USOS: nil
 date of the last return (if any increase has been applied for):

                                                                                     USIS: nil

                                                                                     EMI: nil

                                                                                     LTIP: nil
 Less:  Number of securities issued/allotted under scheme(s) during period:          USOS: nil

                                                                                     USIS: nil

                                                                                     EMI: nil

                                                                                     LTIP: 207,096

 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:          16,030,474
 Number and class of securities originally admitted and the date of admission        USOS Total: 3,882,912

                                                                                     814,424 25 May 2011

                                                                                     1,202,280             8 October 2013

                                                                                     1,466,208             25 May 2017

                                                                                     400,000                30 May 2018

                                                                                     USIS Total: 425,000

                                                                                     425,000 30 November 2018

                                                                                     EMI Total: 8,112,088

                                                                                     1,520,576             25 May 2011

                                                                                     1,467,720             8 October 2013

                                                                                     1,893,792             25 May 2017

                                                                                     790,000                30 May 2018

                                                                                     1,340,000             30 November 2018

                                                                                     1,100,000             2 February 2023

                                                                                     LTIP Total:  15,035,617

                                                                                     4,444,942            2 February 2023

                                                                                     10,590,675          3 November 2023

 

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters        +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative,
consumer-focused, sexual health products, including lead product
Eroxon(®) and development projects WSD4000 and Eroxon(®) Intense. Our core
strength lies in our research, development, regulatory and business
development expertise in developing innovative, clinically proven, insight-led
and effective products to support our customers in the growing sexual health
market.

Sexual health issues are prevalent globally in both men and women. Erectile
Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets,
with approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. 60% of women experience at least one symptom
of impaired sexual response or function in a twelve months period, with only
one in four women seeking professional help and remaining chronically
underserved.

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection fast, addresses significant unmet needs in the ED market. Multiple
license or distribution partnerships are in place for Eroxon(®), across major
consumer markets.

WSD4000 is a project name for our development female sexual health portfolio,
starting with the creation of a range of topical gels under our unique
platform technology, specifically designed to treat symptoms of sexual
dysfunction in women. There is currently no known regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal, lubrication and ability to orgasm.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFBMITMTTMBPF



            Copyright 2019 Regulatory News Service, all rights reserved